CRDF

Cardiff Oncology, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$0.73

Price (1 Year)

$3.17 $0.73

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %0 / %30
Non-compliant assets / Total market cap %17.4 / %30
Non-compliant revenue / Total income %86 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.

Website

Analysis (Turkish): CRDF Hissesi Caiz mi, Helal mi? Cardiff Oncology, Inc. Katılım Analizi